Advertisements



Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On

Agenus: Out Of Favor Immuno-Oncology Pioneer Powers On.....»»

Category: topSource: seekingalphaJul 11th, 2019

Agenus stock shoots up 60% after announcing drug development deal with Gilead

Shares of Agenus Inc. shot up 60% in premarket trade Thursday after the company announced it was partnering with Gilead Sciences Inc. to develop up to five immuno-oncology therapies. Under the deal, Agenus will receive $150 millio.....»»

Category: topSource: marketwatchDec 20th, 2018

Gilead, Agenus enter into immuno-oncology partnership

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2018

Gilead, Agenus enter into immuno-oncology partnership

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 20th, 2018

Roche"s Tecentriq Gets CHMP Recommendation for Breast Cancer

Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by.....»»

Category: worldSource: nytJul 1st, 2019

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small mol.....»»

Category: worldSource: nytJun 26th, 2019

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership.....»»

Category: earningsSource: benzingaJun 25th, 2019

Hemispherx CEO says company has "steady, consistent" progress in immuno-oncology

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2019

Price target on Bristol-Myers stock cut to $51 at UBS

Analysts at UBS cut their price target on shares of Bristol-Myers Squibb Co. on Thursday to $51 from $55 per share, citing lower-than-consensus expectations for the company's immuno-oncology franchise. The firm holds "cautious vi.....»»

Category: topSource: marketwatchJun 13th, 2019

Genocea surges after selection as top 10 featured ASCO immuno-oncology abstract

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 31st, 2019

Dynavax announces layoffs, CEO retirement

Dynavax Technologies Corp. said late Thursday it will focus on its vaccine business and on its first commercial product, a hepatitis B vaccine, looking to unwind its immuno-oncology business. The company will also lay off workers an.....»»

Category: topSource: marketwatchMay 23rd, 2019

NewLink Genetics announces updated NLG802 results at immuno-oncology meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 23rd, 2019

Forty Seven and Acerta in pact to evaluate novel immuno-oncology combination

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2019

Spectrum announces asset purchase, license for immuno-oncology platform

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 9th, 2019

Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates

RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (NASDAQ:CGIX), a leader in enabling precision medicine for immuno-oncology and genomic .....»»

Category: earningsSource: benzingaApr 16th, 2019

Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length hum.....»»

Category: earningsSource: benzingaApr 3rd, 2019

Nektar presents data on its immuno-oncology pipeline candidates

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Trillium expands immuno-oncology pipeline with STING agonist program

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Inovio completes enrollment of Phase 1/2 immuno-oncology trial ahead of schedule

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2019

OSE Immunotherapeutics Reports 2018 Financial Results and Business Update

Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases OSE's partnership business model based on innovative products; Multiple validating partnering milestones generated €35 milli.....»»

Category: earningsSource: benzingaMar 28th, 2019

Merck upgraded to Overweight on immuno-oncology leadership at Morgan Stanley

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 17th, 2018